SEC Comment Letter for Schrodinger, Inc. (SDGR) (CIK 0001490978) (SDGR) — Aug 3, 2020

Schrodinger, Inc. (SDGR) (CIK 0001490978)
Date: Aug. 3, 2020 · CIK: 0001490978 · Accession: 0000000000-20-007084

View on Edgar

AI Filing Summary & Sentiment

Date

August 3, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Schrodinger, Inc. (SDGR) (CIK 0001490978)

Letter

United States securities and exchange commission logo August 3, 2020 Ramy Farid, Ph.D. President and Chief Executive Officer Schrödinger, Inc. 120 West 45th Street, 17th Floor New York, New York 10036 Re:Schrödinger, Inc. Draft Registration Statement on Form S-1 Filed July 30, 2020 CIK No. 0001490978 Dear Dr. Farid: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cynthia T. Mazareas, Esq.

Show Raw Text

United States securities and exchange commission logo
August 3, 2020
Ramy Farid, Ph.D.
President and Chief Executive Officer
Schrödinger, Inc.
120 West 45th Street, 17th Floor
New York, New York 10036
Re:Schrödinger, Inc.
Draft Registration Statement on Form S-1
Filed July 30, 2020
CIK No. 0001490978
Dear Dr. Farid:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Cynthia T. Mazareas, Esq.

SecProbe.io